



SmartPA Criteria Proposal

Drug/Drug Class:	Nuedexta Clinical Edit
First Implementation Date:	February 18, 2021
Revised Date:	October 20, 2022
Prepared for:	MO HealthNet
Prepared by:	MO HealthNet/Conduent
Criteria Status:	<input checked="" type="checkbox"/> Existing Criteria <input type="checkbox"/> Revision of Existing Criteria <input type="checkbox"/> New Criteria

Executive Summary

Purpose: Ensure appropriate utilization and control of Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate)

Why Issue Selected: Nuedexta®, a combination product of dextromethorphan hydrobromide and quinidine sulfate, is the first FDA approved treatment for pseudobulbar affect (PBA). PBA is a condition that typically presents in patients with neurological conditions or injuries that affect the way the brain controls emotion. The condition is characterized by episodes of sudden, uncontrollable, and inappropriate episodes of crying or laughing. PBA has a prevalence of approximately 2 million people in the United States with underlying conditions such as stroke, Alzheimer’s disease, Parkinson’s disease, multiple sclerosis, Lou Gehrig’s disease (ALS), or traumatic brain injury. PBA shares several clinical features of mood disorders, however there are characteristic clinical features and validated scales to assist in determining an appropriate diagnosis and therapy. The Center for Neurologic Study – Lability Scale (CNS-LS) is a self-administered questionnaire that asks about the control of laughter and crying; this scale has been validated in patients with ALS and multiple sclerosis. The Pathological Laughter and Crying Scale (PLACS) is an interviewer administered scale assessing sudden episodes of laughter and crying; this scale has been validated in patients with acute stroke. MO HealthNet will impose clinical criteria to ensure appropriate utilization of Nuedexta therapy.

Program-Specific Information:	Date Range FFS 4-1-2021 to 3-31-2022			
	Drug	Claims	Spend	Avg Spend per Claim
	NUEDEXTA 20-10 MG CAPSULE	814	\$859,799.41	\$1,056.26

- Type of Criteria:** Increased risk of ADE Preferred Drug List
 Appropriate Indications Clinical Edit
- Data Sources:** Only Administrative Databases Databases + Prescriber-Supplied

Setting & Population

- Drug class for review: Nuedexta® (dextromethorphan hydrobromide and quinidine sulfate)
- Age range: All appropriate MO HealthNet participants aged 18 years or older

Approval Criteria

Initial Therapy:

- Participant aged 18 years or older **AND**
- Documented diagnosis of pseudobulbar affect **AND**
- Documentation of baseline episode frequency **AND**
- Participant has a Center for Neurologic Study-Lability Scale (CNS-LS) score of ≥ 13 **OR**
- Participant has a Pathological Laughter and Crying Scale (PLACS) score of ≥ 13

Continuation of therapy:

- Initial approval is for 6 months, renewal of prior authorization may be given for up to 12 months following documentation of the following:
 - Documentation of decrease in CNS-LS score or PLACS score from baseline **AND**
 - Documentation of decrease in episode frequency from baseline

Denial Criteria

- Therapy will be denied if all approval criteria are not met
- Claim exceeds 2 capsules per day
- Documented history of MAOI therapy in the past 45 days
- Documented history of quinidine, quinine, or mefloquine therapy in the past 45 days

Required Documentation

Laboratory Results:
MedWatch Form:

Progress Notes:
Other:

X
X

Disposition of Edit

Denial: Exception code "0682" (Clinical Edit)
Rule Type: CE

Default Approval Period

1 year

References

- NUDEXTA (dextromethorphan hydrobromide and quinidine sulfate) [package insert]. Aliso Viejo, CA: Avanir Pharmaceuticals, Inc.; June 2019.
- Ahmed A, Simmons Z. Pseudobulbar affect: prevalence and management. Ther Clin Risk Manag. 2013;9:483-489. doi:10.2147/TCRM.S53906
- Genetic and Rare Diseases Information Center. Pseudobulbar affect. [Pseudobulbar affect | Genetic and Rare Diseases Information Center \(GARD\) – an NCATS Program \(nih.gov\)](#). Accessed August 9, 2021.
- Avanir Pharmaceuticals, Inc. The Impact of PBA on Your Patients is Substantial. [Impact of PBA on Patients | NUDEXTA® \(dextromethorphan HBr and quinidine sulfate\) \(nuedextahcp.com\)](#). Accessed May 6, 2022.

SmartPA Clinical Proposal Form

© 2022 Conduent Business Services, LLC. All rights reserved. Conduent™ and Conduent Design™ are trademarks of Conduent Business Services, LLC in the United States and/or other countries.

Other company trademarks are also acknowledged.